



## SurModics IVD Introduces A New BioFX(R) TMB Enhanced HRP Membrane Substrate

September 20, 2011

### A Winner of the LifeScience Alley<sup>(R)</sup> 2011 New Technology Showcase!

EDEN PRAIRIE, Minn., Sep 20, 2011 (BUSINESS WIRE) --

SurModics IVD introduces BioFX<sup>(R)</sup> TMB Enhanced HRP Membrane Substrate. SurModics IVD, a wholly owned subsidiary of SurModics, Inc. (Nasdaq: SRDX), is a market leader for immunoassay reagents for diagnostic test kits used to detect absence or presence of disease.

*BioFX* TMB Enhanced HRP Membrane Substrate (ESPM) is the latest addition to SurModics IVD's family of quality, market-proven immunodiagnostic reagents. *BioFX* TMB ESPM's one-component formulation was developed to provide room temperature stability for two years, a unique feature making it an ideal choice for diagnostics kits and point-of-care (POC) applications. *BioFX* TMB ESPM reduces membrane wash out at higher peroxidase concentrations, allowing for measurement of an extended dynamic range. Features of *BioFX* TMB Enhanced HRP Membrane Substrate include:

- One-component formulation - ready to use with no mixing
- Similar sensitivity to most mid- to high-level chemiluminescent membrane substrates without the costly equipment needed for detection
- Stable formulation
  - Two years at 25°C
  - Four years at 4°C
- Extended dynamic range with reduction of wash out at higher peroxidase concentrations

This product was recently selected for presentation in the New Technology Showcase at the LifeScience Alley<sup>(R)</sup> Conference & Expo 2011 to be held in Minneapolis, MN on December 7, 2011. "We are very excited that *BioFX* TMB ESPM was chosen as a winner for the 2011 New Technology Showcase presentation and believe its unique features will provide solutions for the challenges faced by the diagnostics industry for POC and membrane applications." said Gary Maharaj, CEO and president of SurModics. "SurModics remains committed to developing additional products for the *in vitro* diagnostic market, enabling us to better serve our customers' needs."

To learn more about SurModics' *in vitro* diagnostic products, please visit our website ([www.surmodicsivd.com](http://www.surmodicsivd.com)), or contact customer service at 952-500-7200 or [orders@surmodics.com](mailto:orders@surmodics.com).

#### About SurModics, Inc.

SurModics' vision is to extend and improve the lives of patients through technology innovation. The Company partners with the world's foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in improved diagnosis and treatment for patients. Offerings include: drug delivery technologies (coatings, microparticles, nanoparticles, and implants); surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for *in vitro* diagnostic test kits and specialized surfaces for cell culture and microarrays. SurModics, along with its subsidiary SurModics IVD, Inc., is headquartered in Eden Prairie, Minnesota and its SurModics Pharmaceuticals subsidiary is located in Birmingham, Alabama. For more information about the Company, visit [www.surmodics.com](http://www.surmodics.com). The content of SurModics' website is not part of this release or part of any filings the Company makes with the SEC.

#### Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements. Statements that are not historical or current facts, including statements about beliefs and expectations regarding our financial performance for fiscal 2011, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including (1) our ability to successfully identify, negotiate, sign, and close a potential strategic transaction related to our Pharmaceuticals business; (2) the inability to realize the anticipated benefits of any potential transaction regarding our Pharmaceuticals business, if consummated, or of our other recent cost savings initiatives; (3) the potential adverse impact to our business as a result of our announcement to pursue strategic alternatives for our Pharmaceuticals business; (4) developments in the regulatory environment, as well as market and economic conditions, may adversely affect our business operations and profitability; (5) our reliance on third parties (including our customers and licensees) and their failure to successfully develop, obtain regulatory approval for, market and sell products incorporating our technologies may adversely affect our business operations, our ability to realize the full potential of our pipeline, and our ability to achieve our corporate goals; and (6) the factors identified under "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 and updated in our subsequent reports filed with the SEC. These reports are available in the Investors section of our website at [www.surmodics.com](http://www.surmodics.com) and at the SEC website at [www.sec.gov](http://www.sec.gov). Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.

SOURCE: SurModics, Inc.

#### SurModics, Inc.

Tim Arens, 952-500-7000

Vice President Finance & Interim CFO